Biologics Exclusivity Flares Up At TTP Talks In Singapore
The Singapore round of talks to build a Trans-Pacific Partnership trade deal among 11 nations concludes in Singapore with the issue of data exclusivity for innovator biologics still in limbo.
You may also be interested in...
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.